4C Biomed uses a unique and highly sensitive immunological-based screening platform to effectively identify targets for drug discovery and development.
Bringing a wealth of knowledge, experience, and passion to our mission. We work collaboratively to develop innovative solutions that address some of the most pressing challenges in cancer immunotherapy. Our team is committed to excellence, and we strive to develop clinical effective novel therapies that can help improve the health and well-being of cancer patients worldwide.
Chairman & Co-founder Mr. Anthony Angel – Highly experienced professional services firm leader, former Worldwide Managing Partner of Linklaters and Global Co-Chairman and Senior Partner of DLA Piper, leading global business law firm , and Executive Managing Director EMEA of Standard & Poor’s, the leading Financial Services organization.
CEO & Scientific Co-founder Dr. Eyal Greenberg CEO and Scientific Co-founder of 4C Biomed. Experienced in project management and establishment of high-throughput screening platforms. Broad experience in integrative platforms, including cell biology, genetics, immunology and bioinformatic interfaces. Prior to establishing 4C Biomed, Eyal Greenberg served as Chief Operating Officer, Researcher and Team Leader at the Ella Lemelbaum Institute for Immuno-Oncology at Sheba Medical Center. Eyal holds a B.Sc. in Life Sciences, M.Sc. in Biotechnology and Ph.D. in Clinical microbiology and Immunology from Tel Aviv University. In addition, Eyal holds a Master of Business Administration from Bar Ilan University. He is the author of multiple peer-reviewed papers and has won several awards.
Chief Scientific Officer & Co-founder Prof. Markel is a senior medical oncologist, an associate professor at Sackler Faculty of Medicine at Tel Aviv University and Director of Davidoff Cancer Center & Deputy CEO at Rabin Medical Center. He completed his Ph.D. in Immunology in 2004 with highest honors, and his MD at 2005, both at the Hebrew University of Jerusalem, Israel. Gal Markel is an internationally recognized expert in translational tumor immunology and clinical immuno-oncology. He is the author of more than 90 peer-reviewed papers and the inventor of more than 20 patents. He is former Director of the Ella Lemelbaum Institute for Immuno-Oncology at Sheba Medical Center. He co-founded BTC (acquired by DSPG in 2011) and was the scientific founder and Chief Scientific Officer of cCAM Biotherapeutics (acquired by Merck & Co in 2015). Prof. Markel is a highly active speaker and has given countless international talks, including TED MED, and has won many awards, such as from the Israel Cancer Association and the Wolf foundation. He is a co-founder, board member and the secretary of the Israel Association for Immuno-Oncology, and serves on the steering committee of the Israel Society for Cancer Research.
Chief Medical Officer & Co-founder Prof. Jacob Schachter received his MD in 1976 from the Hebrew University, Hadassah Medical Center, Jerusalem, and was recognized as certified specialist in Oncology in 1987. He is full Professor and was Head of Oncology Department in Tel-Aviv University Medical School. Currently he is Chairman of the Ella Lemelbaum Institute for Immuno-Oncology and Skin Cancer at the Sheba Medical Center in Israel. His current medical and scientific work is concentrated on adoptive immunotherapy using Tumor Infiltrating Lymphocytes (TIL) Technology, and in clinical development of modern immunotherapy technologies including checkpoints inhibitors. His group was successful in establishing fruitful collaboration with S. A Rosenberg at the NCI, and with their assistance started treating hematological patients with home-made CAR-T Cells. Prof. Schachter was the head of the SAB of cCAM Bio, that was acquired in 2015 by Merck & Co. He published over 150 original articles in peer reviewed Journals and chapters in books on the subject of melanoma and tumor immunology, and presented his work in many world leading scientific meetings.
VP of Research & Development Dr. Gilli Galore-Haskel joined 4C Biomed in November 2016, upon its establishment. She brings extensive knowledge and experience in melanoma research and cancer immunotherapy. Prior to joining 4C Biomed, she served as Researcher and Project Manager at the Ella Lemelbaum Institute for Immuno-Oncology at Sheba Medical Center. Gilli holds a B.Sc. in Life Sciences and M.Sc. in Human Genetics (with highest honors) and a Ph.D. in Clinical microbiology and Immunology focusing on melanoma immune resistance mechanisms, all from Tel Aviv University. She is the author of multiple peer-reviewed papers and has won several awards, including the EACR Travel Fellowship Award.
Head of Research Dr. Merhavi-Shoham joined 4C Biomed in March 2017, bringing to 4C Biomed extensive knowledge and experience in immunology of cancer and immunotherapy. Prior to joining 4C Biomed, Efrat served as Lab Manager at Bar-Ilan University, Researcher and Project Manager at The Ella Lemelbaum Institute for Immuno-Oncology at Sheba Medical Center. Efrat holds a B.Sc. and M.Sc. in Biotechnology (with honors), Ph.D. in Immunology focusing on TCR gene transfer and immunotherapy and Postdoctoral Fellow in Virology, all from Bar-Ilan University. Efrat has published multiple peer-reviewed papers and has won several awards for her outstanding work.
Head of CMC Dr. Landstein joined 4C Biomed in October 2022. Dorit brings over 20 years of managerial experience in the Israeli biotechnology industry with extensive experience in the field of MAb development. Former CSO at Peles Therapeutics, CEO at MabTrix, VP of R&D at ProtAb as well as various other leadership positions at Procognia (Israel), Compugen, and XTLbio. Dr. Landstein holds a PhD in Biology from Ben-Gurion University, Israel.
Research Manager Roni Bareli joined 4C Biomed in February 2017 after completing her B.Sc. (with highest honors) and M.Sc. in immunology and immunotherapy of cancer, as part of the “Psagot” program for outstanding students at Bar Ilan University. Roni has vast experience in molecular biology, genetic engineering, tissue culture and immunological techniques.
Researcher Dr. Naama Dror joined 4C Biomed in January 2018, brining extensive knowledge and experience in immunology and cancer. Prior to joining 4C Biomed, Naama worked as Researcher at the department of Hematology in Tel Aviv Sourasky Medical Center and for 3 years as Senior Research Assistant at the Ella Lemelbaum Institute for Immuno-Oncology at Sheba Medical Center. Before that, Naama worked as Biological Project Manager at NanoVibronix Corp, a medical device company. Naama holds a B.Sc. in Medical Sciences from the Hebrew University, a M.Sc. in Medical Sciences from Ben Gurion University and a Ph.D. in Cell Biology from Tel Aviv University and completed a GCP course at Sheba Medical Center.
Researcher Dr. Shapiro joined 4C Biomed in December 2019, brining extensive knowledge and experience in cellular and molecular biology and cancer research. Prior to joining 4C Biomed, Mika worked for 6 years as Researcher and Lab Manager at the department of Hematology in Tel Aviv Sourasky Medical Center and before that as Senior Researcher and Lab Manager at the fertility preservation center at Sheba Medical Center. Mika holds a B.Sc (with honors) in molecular biochemistry from the Technion – Israel institute of Technology, a M.Sc. in Medical Sciences and a Ph.D. in Neurobiology both from Tel Aviv University and completed a GCP course at Tel Aviv Sourasky Medical Center.
Administrative Manager Joined 4C Biomed in March 2017. Yael has vast experience in managing.Yael is responsible for communication with suppliers, importing and exporting, ad-hoc projects, HR-related tasks and managing all daily administrative duties.Yael is a graduate of Business Administration from Tel Aviv University.
Our Advisory Committee comprises esteemed experts in the fields of oncology, immunology, and biotechnology.
Antoni Ribas, M.D., Ph.D. is Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA), Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC), Director of the Parker Institute for Cancer Immunotherapy (PICI) Center at UCLA, Chair of the Melanoma Committee at SWOG and President-elect of the American Association for Cancer Research (AACR).
Prof. Ribas is a physician-scientist who conducts laboratory and clinical research in malignant melanoma, focusing on immune checkpoint blockade, gene engineered T cells, and BRAF targeted therapies. He has had a leading role in the clinical development and FDA approval of five new drugs for the treatment of metastatic melanoma. His National Cancer Institute (NCI), State of California and foundation-supported research laboratory develops models of disease to test new therapeutic options, studies mechanism of action of treatments in patients and the molecular mechanisms of therapy resistance. This work has allowed defining mechanisms of response and resistance to modern immunotherapies.
Prof. Ribas is an elected member of the American Society of Clinical Investigation (ASCI), has a Doctor Honoris Causa from the University of Buenos Aires, co-led the Stand Up to Cancer (SU2C)-Cancer Research Institute (CRI)-AACR Immunotherapy Dream Team with the Nobel Laureate James Allison, is the recipient of a NCI Outstanding Investigator Award, was profiled as one of the five Visionaries in Medicine by the New York Times on May 27, 2018, acknowledged as Great Immigrant by the Carnegie Foundation in the New York Time
Dr. Omid Hamid is the Director of the Melanoma Center and Phase I Immuno-Oncology Program at The Angeles Clinic and Research Institute. Dr. Hamid is recognized nationally and internationally as a key opinion leader in Immuno-Oncologic Drug Development and Melanoma Therapeutics. Through his role as the Chief of Immunotherapy and Translational Research patients at The Angeles Clinic have benefited from first in class, paradigm shifting drugs. Dr. Hamid was an investigator in the initial trials with Ipilimumab, Pembrolizumab, Nivolumab, Atazolizumab and Vemurafenib, agents that led to significant survival benefits in the lives of patients. He has been a key investigator on combinations of BRAF/MEK inhibitors and novel immune therapy with PD-1 antibodies and continues to be at the forefront of drug development.
Dr. Kunkel has more than two decades of experience in oncology and immunology drug development and commercialization. Dr. Kunkel presently serves on the Board of Directors of K36 Inc., Nurix Therapeutics, and Oric Pharmaceuticals. She also chairs the scientific advisory board of Profound Bio and serves as a clinical advisor to Atomwise, Elevation and Enliven Therapeutics. She was previously the acting Chief Medical Officer and served on the board of Loxo Oncology (sold to Eli Lilly) and served as an independent BOD member at Curis, Maverick and Harpoon therapeutics. She was formerly Chief Medical Officer at Pharmacyclics (acquired by AbbVie) and CMO at Proteolix, Inc. (acquired by Onyx Pharmaceuticals), where she contributed to the global approvals of cancer therapeutics IMBRUVICA® and Kyprolis®, respectively. Prior to joining the biotechnology industry, Dr. Kunkel spent ten years in academic medicine and served as a faculty member at the Bone Marrow Transplant Unit in the Division of Hematology/Oncology at University of California, Los Angeles. Dr. Kunkel obtained a medical degree from University of Southern California and a bachelor’s degree in biology from University of California, San Diego. She is board certified in internal medicine and held board certifications in hematology and oncology.
Prof. Mandelboim is a principal investigator and a Professor at the Hebrew University of Jerusalem, Israel, where he leads a research laboratory and serves as the head of the Lautenberg Center for General and Tumor Immunology, and the head of the Department of Immunology and Cancer Research. Prof. Mandelboim received his Ph.D. in Immunology from the Weizmann Institute of Science followed by a post-doctorate fellowship at the Harvard Medical School. He then joined the Department of Immunology and Cancer Research at the Faculty of Medicine at the Hebrew University, to establish a laboratory of NK cell biology. To this date, Prof. Mandelboim published more than 180 scientific papers, participated in 3 EU consortium grants, in two Marie Curie student network grants, and won an ERC advanced grant. He obtained grants in a total sum of more than 15,000,000 Euro, received more than 20 awards, and supervised more than 50 Ph.D. students.
Menashe Bar-Eli , Ph.D. is a Professor at the Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX. Prof. Bar-Eli received his Ph.D. in Immunology from the Hebrew University-Hadassah Medical School. The focus of his laboratory is to study the molecular biology of melanoma metastasis. He is a Co-Director of the CCSG Metastasis Program at the Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, a Member at the AACR TME Steering Committee, and a member at the Editorial Boards of Cancer Research, Pigment Cell & Melanoma Research, Cancer and Metastasis Reviews journals. Dr. Bar-Eli is currently the Director of the Cancer Biology Program, UT health Science Center and M.D. Anderson Cancer Center and he is the Co-Director of the Metastasis Cancer Center.